MUMBAI, India, April 17 -- Intellectual Property India has published a patent application (202511095493 A) filed by Dr. Jawed Iqbal; Dr. Tanveer Ahmad; and Dr. Syeda Najidah Shahni, New Delhi, on Oct. 4, 2025, for 'a dual detection of hepatitis b and c viruses using crispr-cas systems and lateral flow assay.'
Inventor(s) include Dr. Jawed Iqbal; Dr. Tanveer Ahmad; and Dr. Syeda Najidah Shahni.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a dual detection of Hepatitis B and C Viruses using CRISPR-Cas systems and Lateral Flow Assay. The present invention includes a hepatitis B virus(HBV) DNA, a hepatitis C virus(HCV) RNA, a CRISPR-Cas enzyme, a single stranded reporter, a crRNA and a single lateral-flow assay(LFA) strip. The CRISPR-Cas12a enzyme is used for a detection of the hepatitis B virus(HBV) DNA. The CRISPR-Cas13a enzyme is used for a detection of the hepatitis C virus(HCV) RNA. The single stranded DNA(ssDNA) reporter is used as a collateral cleavage substrate for the CRISPR-Cas12a enzyme. The single stranded RNA(ssRNA) reporter is used as a collateral cleavage substrate for the CRISPR-Cas13a enzyme. The single lateral-flow assay(LFA) strip having an anti-FAM antibody line, an anti-DIG antibody line and a Streptavidin-coated gold nanoparticles(AuNPs) control line. The dual detection of Hepatitis B and C Viruses provides rapid, affordable, point-of-care diagnostics and on-site method for identifying co-infections."
Disclaimer: Curated by HT Syndication.
